EyePoint, Inc. is under investigation by Pomerantz LLP for potential securities fraud following the announcement that its Phase 3 trial for DURAVYU™ failed to meet the primary endpoint of improving visual acuity compared to a competitor drug. This news caused EyePoint's stock to drop nearly 67% in one day. The investigation will determine if the company or its executives engaged in unlawful business practices. Investors affected by the stock decline are encouraged to contact the law firm for possible class action participation.
Best Buy reported a strong fiscal Q2 2027 with revenue up 3.6% to $9.78 billion and comparable sales rising 4.1%, surpassing expectations. Adjusted diluted EPS increased 15% to $1.47, helped partly by $34 million in tariff refunds. Following these re...
BP, a major global energy company, is actively managing its portfolio by potentially selling oil and gas assets in Egypt to Energean and investing in new projects like a Halliburton contract in Brazil's offshore field. This strategic move aims to enh...
Blockstream has introduced a Bitcoin Improvement Proposal (BIP) called SHRINCS, a post-quantum signature scheme designed to protect Bitcoin from potential quantum computing threats. SHRINCS is already tested on Blockstream’s Liquid sidechain but pres...
Evernorth Holdings received SEC approval for its Form S-4 registration, enabling its merger with Armada Acquisition Corp. II and a Nasdaq listing under the ticker XRPN. The merger is expected to raise over $1 billion, making Evernorth the largest pub...
Radiant World, a Singapore-based iron ore trading firm claiming $9.6 billion in revenue, is losing key partners after allegations of invalid invoices surfaced. Major commodity traders like Vitol, Cargill, and Glencore stopped business with Radiant, t...
